Anxo Pharmaceutical Co., Ltd. (TPEX:6677)
Taiwan · Delayed Price · Currency is TWD 17.70
0.00 (0.00%)
May 29, 2026, 1:55 PM CST
Anxo Pharmaceutical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -34.13 | -57.21 | 21.86 | -12.56 | 19.23 |
Depreciation & Amortization | 75.07 | 75.63 | 73.56 | 73.41 | 73.98 |
Other Amortization | 1.14 | 1.08 | 1 | 0.8 | 0.4 |
Loss (Gain) From Sale of Assets | 0.35 | - | -0.01 | -0.47 | 0.08 |
Asset Writedown & Restructuring Costs | - | - | - | - | -0.06 |
Stock-Based Compensation | 0.8 | 3.85 | 5.31 | 4.74 | 0.75 |
Provision & Write-off of Bad Debts | 0.79 | 0.15 | 0.16 | 0.27 | -0.25 |
Other Operating Activities | -12.26 | -15.4 | 3.54 | -2.02 | 5.67 |
Change in Accounts Receivable | 26.43 | 32.25 | -11.03 | -32.48 | -13.38 |
Change in Inventory | 8.6 | 21.45 | -40.76 | -4.22 | 28.15 |
Change in Accounts Payable | -15.99 | 1.61 | -19.84 | 15.6 | 2.01 |
Change in Unearned Revenue | 1.72 | 3.11 | -7.79 | 17.83 | 0.79 |
Change in Other Net Operating Assets | 2.83 | 45.46 | -28.65 | 10.35 | -39 |
Operating Cash Flow | 55.34 | 111.97 | -2.66 | 71.27 | 78.35 |
Operating Cash Flow Growth | -50.58% | - | - | -9.04% | 30.86% |
Capital Expenditures | -47.74 | -42.34 | -57.83 | -14.59 | -34.85 |
Sale of Property, Plant & Equipment | - | - | 3.35 | 0.47 | - |
Sale (Purchase) of Intangibles | -1.66 | -18.25 | -0.21 | -2.03 | -2.83 |
Investment in Securities | -5.32 | 75.26 | -125.03 | - | - |
Other Investing Activities | -0.5 | 20.59 | 0.48 | -6.26 | 0.32 |
Investing Cash Flow | -55.22 | 35.26 | -179.24 | -22.41 | -37.36 |
Short-Term Debt Issued | 861 | 645 | 809 | 709.38 | 590.45 |
Long-Term Debt Issued | - | - | - | 6.51 | 26 |
Total Debt Issued | 861 | 645 | 809 | 715.89 | 616.45 |
Short-Term Debt Repaid | -798 | -655 | -850.38 | -668 | -575.08 |
Long-Term Debt Repaid | -67.83 | -53.6 | -60.11 | -69.01 | -76.62 |
Total Debt Repaid | -865.83 | -708.6 | -910.49 | -737.01 | -651.7 |
Net Debt Issued (Repaid) | -4.83 | -63.6 | -101.49 | -21.12 | -35.25 |
Issuance of Common Stock | 2.74 | 2.64 | 337.5 | - | - |
Common Dividends Paid | - | -22.25 | - | - | - |
Other Financing Activities | 6.43 | -0.53 | - | -0.6 | 0.68 |
Financing Cash Flow | 4.34 | -83.75 | 236.01 | -21.72 | -34.57 |
Net Cash Flow | 4.46 | 63.48 | 54.11 | 27.14 | 6.42 |
Free Cash Flow | 7.6 | 69.63 | -60.48 | 56.68 | 43.51 |
Free Cash Flow Growth | -89.09% | - | - | 30.27% | -0.90% |
Free Cash Flow Margin | 0.90% | 7.78% | -6.44% | 6.54% | 5.28% |
Free Cash Flow Per Share | 0.14 | 1.25 | -1.17 | 1.18 | 0.90 |
Cash Interest Paid | 16.55 | 16.79 | 18.25 | 15.05 | 12.77 |
Cash Income Tax Paid | 0.93 | 11.38 | 11.71 | 9.64 | -0.58 |
Levered Free Cash Flow | -2.79 | 76.1 | -50.15 | 62.13 | 43.95 |
Unlevered Free Cash Flow | 7.61 | 86.52 | -38.85 | 71.62 | 51.93 |
Change in Working Capital | 23.6 | 103.88 | -108.07 | 7.09 | -21.45 |